Azacitidine
- Generic Name
- Azacitidine
- Brand Names
- Onureg, Vidaza, Azacitidine Accord, Azacitidine betapharm, Azacitidine Mylan, Azacitidine Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O5
- CAS Number
- 320-67-2
- Unique Ingredient Identifier
- M801H13NRU
- Background
Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity. Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. As an analogue of cytidine, it is able to incorporate into ...
- Indication
Azacitidine (for subcutaneous or intravenous use) is indicated for the treatment of adult patients with the following French-American-British (FAB) myelodysplastic syndrome (MDS) subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemi...
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Refractory Anemia, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess of Blasts (RAEB), Refractory Anemia With Ringed Sideroblasts, Newly diagnosed Juvenile Myelomonocytic Leukaemias (JMML)
- Associated Therapies
- -
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 60
- Registration Number
- NCT06744556
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06694454
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
ICP-248 in Combination with Azacitidine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia(AML) or Previously Treated Relapsed/Refractory Subjects with Acute Myelogenous Leukemia(R/R AML).
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06656494
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
- Conditions
- Interventions
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT06647862
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Zhujiang, Guangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangzhou, China
🇨🇳The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Aptevo Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT06634394
A Phase Ib Study of Rezatapopt in Combination With Azacitidine or Azacitidine and Venetoclax in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
- Conditions
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT06616636
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5-Azacytidine with Steroids for Gastrointestinal GVHD (5-AZA for GVHD)
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT06598332
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL
- Conditions
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Target Recruit Count
- 30
- Registration Number
- NCT06578546
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Extension Study, Pilot, Compassionate Use of Azacitidine 300 mg Film Coated Tablets for Acute Myeloid Leukaemia (AML) Patients
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06572982
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Institut Paoli-Calmettes
- Target Recruit Count
- 50
- Registration Number
- NCT06557421
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.